HRP20171897T1 - Kombinirana terapija afukoziliranog protutijela cd20 s konjugatom cd79b protutijelo-lijek - Google Patents
Kombinirana terapija afukoziliranog protutijela cd20 s konjugatom cd79b protutijelo-lijekInfo
- Publication number
- HRP20171897T1 HRP20171897T1 HRP20171897TT HRP20171897T HRP20171897T1 HR P20171897 T1 HRP20171897 T1 HR P20171897T1 HR P20171897T T HRP20171897T T HR P20171897TT HR P20171897 T HRP20171897 T HR P20171897T HR P20171897 T1 HRP20171897 T1 HR P20171897T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- afucosylated
- combination therapy
- drug conjugate
- cd79b
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361818821P | 2013-05-02 | 2013-05-02 | |
EP14724662.3A EP2992016B1 (en) | 2013-05-02 | 2014-04-30 | Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate |
PCT/EP2014/058827 WO2014177615A2 (en) | 2013-05-02 | 2014-04-30 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171897T1 true HRP20171897T1 (hr) | 2018-01-12 |
Family
ID=50733021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171897TT HRP20171897T1 (hr) | 2013-05-02 | 2017-12-06 | Kombinirana terapija afukoziliranog protutijela cd20 s konjugatom cd79b protutijelo-lijek |
Country Status (27)
Country | Link |
---|---|
US (4) | US20140356352A1 (hr) |
EP (1) | EP2992016B1 (hr) |
JP (1) | JP6306154B2 (hr) |
KR (1) | KR101824311B1 (hr) |
CN (1) | CN105189558A (hr) |
AR (1) | AR096183A1 (hr) |
AU (1) | AU2014261454B2 (hr) |
BR (1) | BR112015027309A2 (hr) |
CA (1) | CA2908658C (hr) |
DK (1) | DK2992016T3 (hr) |
ES (1) | ES2653424T3 (hr) |
HK (1) | HK1213575A1 (hr) |
HR (1) | HRP20171897T1 (hr) |
HU (1) | HUE035171T2 (hr) |
IL (1) | IL242163B (hr) |
LT (1) | LT2992016T (hr) |
MX (1) | MX359964B (hr) |
MY (1) | MY181960A (hr) |
NO (1) | NO3080382T3 (hr) |
NZ (1) | NZ713745A (hr) |
PL (1) | PL2992016T3 (hr) |
PT (1) | PT2992016T (hr) |
RS (1) | RS56688B1 (hr) |
RU (1) | RU2670971C9 (hr) |
SG (1) | SG11201509009WA (hr) |
SI (1) | SI2992016T1 (hr) |
WO (1) | WO2014177615A2 (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101981055B (zh) * | 2008-01-31 | 2016-03-09 | 健泰科生物技术公司 | 抗cd79b抗体和免疫偶联物及使用方法 |
WO2016049214A1 (en) * | 2014-09-23 | 2016-03-31 | Genentech, Inc. | METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES |
US20170315132A1 (en) * | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
US20180140703A1 (en) * | 2016-11-18 | 2018-05-24 | The Regents Of The University California | Tumor radiosensitization with antibody conjugates |
EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
CN113384711A (zh) * | 2018-04-13 | 2021-09-14 | 基因泰克公司 | 稳定的抗cd79b免疫缀合物制剂 |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
EP3919516A4 (en) | 2019-01-28 | 2022-11-30 | Tuojie Biotech (Shanghai) Co., Ltd. | ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
CN112094345B (zh) * | 2020-06-01 | 2024-01-05 | 普众发现医药科技(上海)有限公司 | 可应用于肿瘤细胞捕获的小鼠抗免疫球蛋白关联βCD79b的单克隆抗体 |
AU2021317378A1 (en) * | 2020-07-27 | 2023-03-09 | Tuojie Biotech (Shanghai) Co., Ltd. | Anti-CD79B antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6922984B2 (en) * | 2003-08-27 | 2005-08-02 | Valero Refining Company - California | Heat recovery circuit |
RS54450B1 (en) * | 2003-11-05 | 2016-06-30 | Roche Glycart Ag | ANTIGEN-BINDING MOLECULES WITH INCREASED BINDING AFFINITY FOR FC RECEPTOR AND EFFECTOR FUNCTION |
ES2382627T3 (es) * | 2004-06-29 | 2012-06-12 | B.R.A.H.M.S Gmbh | Nuevos anticuerpos monoclonales estimuladores o bloqueadores de la tiroides, secuencias peptídicas que corresponden a sus regiones variables, y sus usos en medicina diagnóstica, preventiva y terapéutica |
SG183023A1 (en) | 2007-07-16 | 2012-08-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
CN101981055B (zh) * | 2008-01-31 | 2016-03-09 | 健泰科生物技术公司 | 抗cd79b抗体和免疫偶联物及使用方法 |
-
2014
- 2014-04-30 NZ NZ713745A patent/NZ713745A/en unknown
- 2014-04-30 HU HUE14724662A patent/HUE035171T2/en unknown
- 2014-04-30 MY MYPI2015703902A patent/MY181960A/en unknown
- 2014-04-30 JP JP2016511053A patent/JP6306154B2/ja active Active
- 2014-04-30 AR ARP140101794A patent/AR096183A1/es unknown
- 2014-04-30 WO PCT/EP2014/058827 patent/WO2014177615A2/en active Application Filing
- 2014-04-30 KR KR1020157034237A patent/KR101824311B1/ko active IP Right Grant
- 2014-04-30 PL PL14724662T patent/PL2992016T3/pl unknown
- 2014-04-30 SI SI201430518T patent/SI2992016T1/en unknown
- 2014-04-30 LT LTEP14724662.3T patent/LT2992016T/lt unknown
- 2014-04-30 EP EP14724662.3A patent/EP2992016B1/en active Active
- 2014-04-30 PT PT147246623T patent/PT2992016T/pt unknown
- 2014-04-30 BR BR112015027309A patent/BR112015027309A2/pt not_active Application Discontinuation
- 2014-04-30 ES ES14724662.3T patent/ES2653424T3/es active Active
- 2014-04-30 DK DK14724662.3T patent/DK2992016T3/en active
- 2014-04-30 US US14/266,443 patent/US20140356352A1/en not_active Abandoned
- 2014-04-30 SG SG11201509009WA patent/SG11201509009WA/en unknown
- 2014-04-30 RU RU2015151454A patent/RU2670971C9/ru active
- 2014-04-30 CN CN201480023250.5A patent/CN105189558A/zh active Pending
- 2014-04-30 AU AU2014261454A patent/AU2014261454B2/en active Active
- 2014-04-30 MX MX2015015091A patent/MX359964B/es active IP Right Grant
- 2014-04-30 RS RS20171301A patent/RS56688B1/sr unknown
- 2014-04-30 CA CA2908658A patent/CA2908658C/en active Active
- 2014-12-03 NO NO14820742A patent/NO3080382T3/no unknown
-
2015
- 2015-10-19 IL IL242163A patent/IL242163B/en active IP Right Grant
-
2016
- 2016-02-11 HK HK16101476.3A patent/HK1213575A1/zh unknown
-
2017
- 2017-11-09 US US15/808,795 patent/US20180133315A1/en not_active Abandoned
- 2017-12-06 HR HRP20171897TT patent/HRP20171897T1/hr unknown
-
2018
- 2018-08-10 US US16/101,203 patent/US20180344848A1/en not_active Abandoned
-
2020
- 2020-12-18 US US17/127,697 patent/US20210138065A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171897T1 (hr) | Kombinirana terapija afukoziliranog protutijela cd20 s konjugatom cd79b protutijelo-lijek | |
IL267618B (en) | Methods of producing antibody-drug conjugates | |
IL241277A0 (en) | Antibody-drug conjugates | |
HK1213580A1 (zh) | 用於修飾抗體以製備免疫綴合物的特定位點 | |
IL244960A0 (en) | Combination therapy with an apocosylated cd20 antibody with a btk inhibitor | |
HK1211962A1 (en) | Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate cd20 cd22 - | |
ZA201508487B (en) | Antibody drug conjugates | |
EP2968600A4 (en) | Antibody drug conjugates | |
IL245437A0 (en) | Antibodies against efna4 and antibody-drug pairs | |
GB201310472D0 (en) | Antibody-drug conjugates |